380 related articles for article (PubMed ID: 25990388)
21. Inflammatory bowel diseases: from pathogenesis to laboratory testing.
Basso D; Zambon CF; Plebani M
Clin Chem Lab Med; 2014 Apr; 52(4):471-81. PubMed ID: 24108210
[TBL] [Abstract][Full Text] [Related]
22. Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia.
Saadah OI; Al-Mughales JA
Arab J Gastroenterol; 2013 Jun; 14(2):78-82. PubMed ID: 23820506
[TBL] [Abstract][Full Text] [Related]
23. Genetics of Inflammatory Bowel Diseases.
McGovern DP; Kugathasan S; Cho JH
Gastroenterology; 2015 Oct; 149(5):1163-1176.e2. PubMed ID: 26255561
[TBL] [Abstract][Full Text] [Related]
24. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease.
Arai R
Postgrad Med; 2010 Jul; 122(4):177-85. PubMed ID: 20675980
[TBL] [Abstract][Full Text] [Related]
25. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
26. Fecal markers: calprotectin and lactoferrin.
Abraham BP; Kane S
Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
[TBL] [Abstract][Full Text] [Related]
27. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
Langhorst J; Boone J
Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer.
James JP; Riis LB; Malham M; Høgdall E; Langholz E; Nielsen BS
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114313
[TBL] [Abstract][Full Text] [Related]
29. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
30. Towards personalized care in IBD.
Gerich ME; McGovern DP
Nat Rev Gastroenterol Hepatol; 2014 May; 11(5):287-99. PubMed ID: 24345887
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory bowel diseases and Takayasu's arteritis: coincidence or association?
Kilic L; Kalyoncu U; Karadag O; Akdogan A; Dogan I; Bilgen SA; Kiraz S; Ertenli I
Int J Rheum Dis; 2016 Aug; 19(8):814-8. PubMed ID: 26913584
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory bowel disease detection and monitoring by measuring biomarkers in non-invasively collected colorectal mucus.
Loktionov A; Chhaya V; Bandaletova T; Poullis A
J Gastroenterol Hepatol; 2017 May; 32(5):992-1002. PubMed ID: 27787913
[TBL] [Abstract][Full Text] [Related]
33. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
McRae BL; Levin AD; Wildenberg ME; Koelink PJ; Bousquet P; Mikaelian I; Sterman AS; Bryant S; D'Haens G; Kamath R; Salfeld J; van den Brink GR
J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698
[TBL] [Abstract][Full Text] [Related]
34. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA in inflammatory bowel disease: Translational research and clinical implication.
Fisher K; Lin J
World J Gastroenterol; 2015 Nov; 21(43):12274-82. PubMed ID: 26604636
[TBL] [Abstract][Full Text] [Related]
36. Exome sequencing analysis reveals variants in primary immunodeficiency genes in patients with very early onset inflammatory bowel disease.
Kelsen JR; Dawany N; Moran CJ; Petersen BS; Sarmady M; Sasson A; Pauly-Hubbard H; Martinez A; Maurer K; Soong J; Rappaport E; Franke A; Keller A; Winter HS; Mamula P; Piccoli D; Artis D; Sonnenberg GF; Daly M; Sullivan KE; Baldassano RN; Devoto M
Gastroenterology; 2015 Nov; 149(6):1415-24. PubMed ID: 26193622
[TBL] [Abstract][Full Text] [Related]
37. How to use faecal calprotectin in management of paediatric inflammatory bowel disease.
Saha A; Tighe MP; Batra A
Arch Dis Child Educ Pract Ed; 2016 Jun; 101(3):124-8. PubMed ID: 26848103
[TBL] [Abstract][Full Text] [Related]
38. New serologic markers for inflammatory bowel disease diagnosis.
Dotan I
Dig Dis; 2010; 28(3):418-23. PubMed ID: 20926866
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
[TBL] [Abstract][Full Text] [Related]
40. Drug monitoring of biologics in inflammatory bowel disease.
Eser A; Primas C; Reinisch W
Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
